Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults

Sunday, November 3, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VKTX is initiating a first-in-human study for VK2735, an oral GLP-1/GIP co-agonist. This study aims to evaluate the safety and efficacy of VK2735 in healthy adults. The development of VK2735 could provide a novel treatment option in the biopharma landscape.
Price reaction · baseline $72.88 (2024-11-01 close) · 1 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-13.4%
day 1
-11.3%
day 3
-5.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • VK2735 is undergoing a first-in-human study.
  • The oral formulation may offer a new treatment option.
  • The study involves healthy adults, indicating initial safety testing.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

• About Management Board of Directors Careers
• Pipeline Overview VK2735 VK3019 VK2809 VK0214 VK5211 Publications
• Investors Overview Stock Information Stock Chart Historical Price Lookup News & Events Press Releases Webcasts SEC Filings Analyst Coverage Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition Shareholder Services Information Request E-mail Alerts Investor Relations Contacts Corporate Presentation
• Contact
• Management
• Board of Directors
• Careers
• Overview
• VK2735
• VK3019
• VK2809
• VK0214
• VK5211
• Publications
• Overview
• Stock Information Stock Chart Historical Price Lookup
• News & Events Press Releases Webcasts
• SEC Filings
• Analyst Coverage
• Corporate Governance Governance Highlights Mangement Board of Directors Committee Composition
• Shareholder Services Information Request E-mail Alerts Investor Relations Contacts
• Corporate Presentation
• Stock Chart
• Historical Price Lookup
• Press Releases
• Webcasts
• Governance Highlights
• Mangement
• Board of Directors
• Committee Composition
• Information Request
• E-mail Alerts
• Investor Relations Contacts

Frequently Asked Questions

What is VK2735?

VK2735 is an oral formulation of a GLP-1/GIP co-agonist developed by VKTX.

Who is participating in the VK2735 study?

The study involves healthy adults to evaluate the safety and efficacy of VK2735.

What is the goal of the VK2735 study?

The goal is to assess the safety and potential effectiveness of VK2735.

ShareAdd on Google
Tags: VKTX Viatris Investor Conferences Healthcare VK2735 GLP-1 GIP oral formulation
Last updated: Nov 3, 2024

Biotech snapshot

Cash runway
$502M liquidity · $42M/mo burn
~11 mo
Medium dilution risk
Lead asset
VK2735Phase 3
Weight Loss →

Catalyst track record

+53%
best trade around VKTX's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for VKTX.

See every catalyst's timing & PoA →